Oppenheimer Reiterates Outperform Rating on Abeona Therapeutics (ABEO) following earnings

March 17, 2026 5:10 PM

Oppenheimer analyst Jeff Jones reiterated an Outperform rating and $22.00 price target on Abeona Therapeutics (NASDAQ: ABEO)The analyst commented, "On ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found